跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 278 条关于
“Hyperphosphatemia”
全部
278
临床试验
232
药物
4
机构
0
资讯
42
去年
China Approves First-in-Class Tenapanor for Hyperphosphatemia in Dialysis Patients
8个月前
Unicycive Therapeutics Resubmits NDA for Novel Phosphate Binder Targeting Hyperphosphatemia in Dialysis Patients
去年
Alebund's AP301 Meets Primary Endpoint in Phase 3 Trial for Hyperphosphatemia in Dialysis Patients
上个月
Bone Resorption and Constipation Predict Higher Tenapanor Dose Requirements in Dialysis Patients with Hyperphosphatemia
去年
Unicycive's OLC Receives FDA Acceptance for Hyperphosphatemia NDA
去年
Unicycive's OLC Receives FDA Acceptance for Hyperphosphatemia Treatment
去年
Unicycive's Hyperphosphatemia Drug, Oxylanthanum Carbonate, Awaits FDA Decision in June
去年
FDA Accepts Unicycive's Oxylanthanum Carbonate (OLC) Application for Hyperphosphatemia Treatment
2年前
Unicycive Submits NDA to FDA for Oxylanthanum Carbonate to Treat Hyperphosphatemia in CKD Patients on Dialysis
去年
FDA Accepts Unicycive's NDA for Oxylanthanum Carbonate to Treat Hyperphosphatemia in CKD Patients on Dialysis
第 1 页,共 5 页
上一页
下一页